149 related articles for article (PubMed ID: 8280712)
1. Generation of donor-derived antileukemic cytotoxic T-lymphocyte responses for treatment of relapsed leukemia after allogeneic HLA-identical bone marrow transplantation.
Falkenburg JH; Faber LM; van den Elshout M; van Luxemburg-Heijs SA; Hooftman-den Otter A; Smit WM; Voogt PJ; Willemze R
J Immunother Emphasis Tumor Immunol; 1993 Nov; 14(4):305-9. PubMed ID: 8280712
[TBL] [Abstract][Full Text] [Related]
2. Generation of CD4+ cytotoxic T-lymphocyte clones from a patient with severe graft-versus-host disease after allogeneic bone marrow transplantation: implications for graft-versus-leukemia reactivity.
Faber LM; van Luxemburg-Heijs SA; Veenhof WF; Willemze R; Falkenburg JH
Blood; 1995 Oct; 86(7):2821-8. PubMed ID: 7670118
[TBL] [Abstract][Full Text] [Related]
3. Generation of leukemia-reactive cytotoxic T lymphocyte clones from the HLA-identical bone marrow donor of a patient with leukemia.
Faber LM; van Luxemburg-Heijs SA; Willemze R; Falkenburg JH
J Exp Med; 1992 Nov; 176(5):1283-9. PubMed ID: 1402674
[TBL] [Abstract][Full Text] [Related]
4. Minor histocompatibility antigen-specific, leukemia-reactive cytotoxic T cell clones can be generated in vitro without in vivo priming using chronic myeloid leukemia cells as stimulators in the presence of alpha-interferon.
Faber LM; van Luxemburg-Heijs SA; Rijnbeek M; Willemze R; Falkenburg JH
Biol Blood Marrow Transplant; 1996 Feb; 2(1):31-6. PubMed ID: 9078352
[TBL] [Abstract][Full Text] [Related]
5. Multiple minor histocompatibility antigen disparities between a recipient and four HLA-identical potential sibling donors for bone marrow transplantation.
Marijt EA; Veenhof WF; Goulmy E; Kluck PM; Brand A; Willemze R; van Rood JJ; Falkenburg JH
Hum Immunol; 1993 Aug; 37(4):221-8. PubMed ID: 8300407
[TBL] [Abstract][Full Text] [Related]
6. Phase I/II feasibility study evaluating the generation of leukemia-reactive cytotoxic T lymphocyte lines for treatment of patients with relapsed leukemia after allogeneic stem cell transplantation.
Marijt E; Wafelman A; van der Hoorn M; van Bergen C; Bongaerts R; van Luxemburg-Heijs S; van den Muijsenberg J; Wolbers JO; van der Werff N; Willemze R; Falkenburg F
Haematologica; 2007 Jan; 92(1):72-80. PubMed ID: 17229638
[TBL] [Abstract][Full Text] [Related]
7. Studies on the mechanism of tolerance or graft-versus-host disease in allogeneic bone marrow recipients at the level of cytotoxic T-cell precursor frequencies.
Irschick EU; Hladik F; Niederwieser D; Nussbaumer W; Holler E; Kaminski E; Huber C
Blood; 1992 Mar; 79(6):1622-8. PubMed ID: 1547351
[TBL] [Abstract][Full Text] [Related]
8. Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies.
Naparstek E; Nagler A; Or R; Kapelushnik J; Slavin S
Clin Transpl; 1996; ():281-90. PubMed ID: 9286578
[TBL] [Abstract][Full Text] [Related]
9. Multiple minor histocompatibility antigen-specific cytotoxic T lymphocyte clones can be generated during graft rejection after HLA-identical bone marrow transplantation.
Marijt WA; Kernan NA; Diaz-Barrientos T; Veenhof WF; O'Reilly RJ; Willemze R; Falkenburg JH
Bone Marrow Transplant; 1995 Jul; 16(1):125-32. PubMed ID: 7581111
[TBL] [Abstract][Full Text] [Related]
10. Differential roles of IL-1 and TNF-alpha on graft-versus-host disease and graft versus leukemia.
Hill GR; Teshima T; Gerbitz A; Pan L; Cooke KR; Brinson YS; Crawford JM; Ferrara JL
J Clin Invest; 1999 Aug; 104(4):459-67. PubMed ID: 10449438
[TBL] [Abstract][Full Text] [Related]
11. In vitro separation of host specific graft-versus-host and graft-versus-leukemia cytotoxic T cell activities.
van Lochem E; de Gast B; Goulmy E
Bone Marrow Transplant; 1992 Aug; 10(2):181-3. PubMed ID: 1525608
[TBL] [Abstract][Full Text] [Related]
12. The graft-vs.-leukemia effect. Implications for post-marrow transplant antileukemia treatment.
Sosman JA; Sondel PM
Am J Pediatr Hematol Oncol; 1993 May; 15(2):185-95. PubMed ID: 8498642
[TBL] [Abstract][Full Text] [Related]
13. Recognition of clonogenic leukemic cells, remission bone marrow and HLA-identical donor bone marrow by CD8+ or CD4+ minor histocompatibility antigen-specific cytotoxic T lymphocytes.
Faber LM; van der Hoeven J; Goulmy E; Hooftman-den Otter AL; van Luxemburg-Heijs SA; Willemze R; Falkenburg JH
J Clin Invest; 1995 Aug; 96(2):877-83. PubMed ID: 7635982
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxic T-lymphocyte-defined human minor histocompatibility antigens with a restricted tissue distribution.
Warren EH; Greenberg PD; Riddell SR
Blood; 1998 Mar; 91(6):2197-207. PubMed ID: 9490709
[TBL] [Abstract][Full Text] [Related]
15. Minor histocompatibility antigen-specific cytotoxic T cell lines, capable of lysing human hematopoietic progenitor cells, can be generated in vitro by stimulation with HLA-identical bone marrow cells.
Marijt WA; Veenhof WF; Brand A; Goulmy E; Fibbe WE; Willemze R; van Rood JJ; Falkenburg JH
J Exp Med; 1991 Jan; 173(1):101-9. PubMed ID: 1985117
[TBL] [Abstract][Full Text] [Related]
16. The role of B7 costimulation by murine acute myeloid leukemia in the generation and function of a CD8+ T-cell line with potent in vivo graft-versus-leukemia properties.
Boyer MW; Vallera DA; Taylor PA; Gray GS; Katsanis E; Gorden K; Orchard PJ; Blazar BR
Blood; 1997 May; 89(9):3477-85. PubMed ID: 9129056
[TBL] [Abstract][Full Text] [Related]
17. Specific recognition of human leukemic cells by allogeneic T cell lines.
Sosman JA; Oettel KR; Hank JA; Fisch P; Sondel PM
Transplantation; 1989 Sep; 48(3):486-95. PubMed ID: 2571206
[TBL] [Abstract][Full Text] [Related]
18. Graft-versus-host disease prevention in allogeneic bone marrow transplantation from histocompatible siblings. A pilot study using immunotoxins for T cell depletion of donor bone marrow.
Filipovich AH; Vallera DA; Youle RJ; Haake R; Blazar BR; Arthur D; Neville DM; Ramsay NK; McGlave P; Kersey JH
Transplantation; 1987 Jul; 44(1):62-9. PubMed ID: 3299923
[TBL] [Abstract][Full Text] [Related]
19. A novel minor histocompatibility antigen recognized by HLA-A31 restricted cytotoxic T lymphocytes generated from HLA-identical bone marrow donor lymphocytes.
Yazaki M; Takahashi T; Andho M; Akatsuka Y; Ito T; Miyake Y; Ito Y; Nakamura S; Wada Y
Bone Marrow Transplant; 1999 Jul; 24(2):129-37. PubMed ID: 10455340
[TBL] [Abstract][Full Text] [Related]
20. Alloreactivity and the predictive value of anti-recipient specific interleukin 2 producing helper T lymphocyte precursor frequencies for alloreactivity after bone marrow transplantation.
Russell CA
Dan Med Bull; 2002 May; 49(2):89-108. PubMed ID: 12064093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
